Pharmacoeconomic Analysis of Osimertinib Compared to Earlier‐Generation EGFR Inhibitors in EGFR ‐Mutated NSCLC : A Systematic Review
Cancer Medicine · 2026-07 · 15 (7)
DOI: 10.1002/cam4.72129 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Cancer Medicine, online erschienen am 22.07.2026. Verfasst von Nicola Perrotta und 4 weiteren Autor:innen. Beteiligte Einrichtung: Policlinico Umberto I Hospital, Sapienza University, Rome, Italy. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Aniline Compounds, Lung Neoplasms, Acrylamides. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Osimertinib has reshaped the treatment of EGFR‐mutated non‐small cell lung cancer (NSCLC), but its high cost raises persistent questions about value for money.
Objectives
To review economic evaluations of osimertinib in EGFR‐mutated NSCLC and identify the drivers of cost‐effectiveness across first‐line, second‐line/sequential, and adjuvant settings in North America and Europe.
Methods
This review was registered with PROSPERO (CRD420251139947) and conducted in accordance with PRISMA 2020. We searched PubMed/MEDLINE, Embase, Web of Science Core Collection, and the Cochrane Library through August 2025 for peer‐reviewed economic evaluations comparing osimertinib with chemotherapy or earlier‐generation EGFR tyrosine kinase inhibitors from a payer perspective. Reporting quality was appraised with CHEERS 2022. Given heterogeneity in models, pricing, and survival extrapolation, results were synthesized narratively, each incremental cost‐effectiveness ratio (ICER) interpreted against its own jurisdiction's willingness‐to‐pay (WTP) threshold.
Results
Nine studies published between 2018 and 2024 were included. First‐line osimertinib improved outcomes but at ICERs of $151,922–$231,123/QALY (US) and €128,343–€273,895/QALY (Europe), exceeding local thresholds. Second‐line T790M‐positive estimates were favorable and context‐dependent ($159,126/QALY US; £41,705/QALY UK under end‐of‐life criteria). Adjuvant results were most divergent: cost‐effective under cure‐fraction assumptions but unfavorable when benefit was modeled as delayed recurrence. Price, overall‐survival (OS) extrapolation, sequencing, and local WTP thresholds were dominant.
Conclusions
Osimertinib confers meaningful clinical benefit, but its value for money is context‐specific and often uncertain at current list prices. These conclusions rest on few heterogeneous models and warrant caution; sustainable use will depend on price reductions, patient prioritization, maturation of OS data, and outcome‐based reimbursement.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Policlinico Umberto I Hospital, Sapienza University, Rome, Italy.
- Department of Chemistry and Technology of Drugs, Sapienza University, Rome, Italy.
ORCID-Profile: Nicola Perrotta
Zitieren
APA
Perrotta, N., Coluccia, A., Rossi, F., Amato, G., & Polito, G. (2026). Pharmacoeconomic Analysis of Osimertinib Compared to Earlier‐Generation EGFR Inhibitors in EGFR ‐Mutated NSCLC : A Systematic Review. Cancer Medicine, 15(7). https://doi.org/10.1002/cam4.72129
Vancouver
Perrotta N, Coluccia A, Rossi F, Amato G, Polito G. Pharmacoeconomic Analysis of Osimertinib Compared to Earlier‐Generation EGFR Inhibitors in EGFR ‐Mutated NSCLC : A Systematic Review. Cancer Medicine. 2026;15(7). doi:10.1002/cam4.72129
BibTeX
@article{Perrotta2026,
author = {Perrotta, Nicola and Coluccia, Adriana and Rossi, Francesca and Amato, Giulia and Polito, Giacomo},
title = {Pharmacoeconomic Analysis of Osimertinib Compared to Earlier‐Generation EGFR Inhibitors in EGFR ‐Mutated NSCLC : A Systematic Review},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {7},
doi = {10.1002/cam4.72129}
}
EUVIMED